Navigation Links
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Date:12/29/2008

dicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic tools, which is unproven and may never lead to commercially accepted products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop and commercialize its candidate tools, products and services; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta's technology; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media & Investors, Ron Kamienchick, T: +1-(646)-509-1893, E:

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. /C O R R E C T I O N -- Rosetta Genomics Ltd/
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
6. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
7. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
8. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
9. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Controlled Substance ... Alliance, which helps companies check the legal requirements around ... expand to China. , As their international operations ... globally adopting software solutions built as a result of ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
...  Today, the Global Probiotics Council (GPC), a committee formed ... launch of the fifth annual Young Investigator Grant for ... in the amount of $50,000, to promising young researchers. ... the role of probiotics and gastrointestinal microbiota in health ...
... Arcion Therapeutics, a clinical stage biotechnology company developing ... received notice of allowance for a US Patent for ... ARC-2022 is being developed by Arcion for pain associated ... has been evaluated in a single-dose Phase 1 pharmacokinetic ...
... Jan. 4, 2012  Verify Brand™ announces the release ... 4.0 software. VB Enterprise 4.0 is a suite ... client and mobile software applications that enable comprehensive ... Trace® across the supply chain. VB Enterprise ...
Cached Biology Technology:Fifth Cycle of Probiotics & Microbiota Research Grant Announced 2Fifth Cycle of Probiotics & Microbiota Research Grant Announced 3Fifth Cycle of Probiotics & Microbiota Research Grant Announced 4Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain 2Verify Brandâ„¢ Announces the Release of VB Enterprise 4.0 2
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... FL, December 28, 2010 Scientists from the Florida campus ... between a structural hepatitis C virus protein (HCV) and a ... a novel method of inhibiting the production of the virus ... development. The study was published in the January ...
... CANADA A study in HortTechnology featured ... solar heat radiation and temperatures during the hot summer ... researchers, was the first investigation into the effects of ... method. Results showed that the technology improved greenhouse and ...
... CT Woody ornamental plants with colorful or unusually ... specialty niche in cut flower production markets. These unique ... distinct benefits such as extended growing seasons, respectable financial ... from single plantings. A research team from the ...
Cached Biology News:Scripps Research scientists identify key interaction in hepatitis C virus 2New technology improves greenhouse, plant microclimates 2Willow cut-stem growers surveyed 2
Without sodium bicarbonate. Sterile, Cell culture tested...
... IFNγ ELISPOT (enzyme-lined immunospot) Kit analyzes interferon ... level. A spot forms at the site ... (either using a dissection microscope or automated ... number of cells added to the microplate. ...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,515-8) or contact ...
... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
Biology Products: